colorect
cancer
crc
account
cancer
death
annual
therebi
second
common
caus
cancerrel
death
men
women
europ
upon
diagnosi
patient
alreadi
develop
local
advanc
metastasis
diseas
develop
metastasi
followup
though
diagnos
treat
earli
overal
surviv
rate
around
unfortun
current
suitabl
tumour
marker
earli
diagnosi
crc
noninvas
diagnost
method
could
suitabl
screen
patient
measur
serum
carcinoembryon
antigen
cea
level
faecal
occult
blood
test
faecal
dna
analysi
low
sensit
andor
specif
recent
develop
technolog
like
genom
proteom
profil
provid
new
opportun
search
diagnost
biomark
microarray
analys
yield
highli
predict
prognost
profil
eg
breast
cancer
howev
genom
analys
depend
avail
tissu
materi
assess
acquir
genet
chang
thu
less
suitabl
screen
larg
popul
followup
patient
surgeri
contrast
proteom
profil
done
easilyaccess
bodi
fluid
like
serum
assess
treatment
crc
tissu
constantli
perfus
blood
tumour
tissueorigin
protein
also
tissueprocess
endogen
protein
repres
blood
reflect
actual
state
individu
health
sever
techniqu
use
protein
profil
overview
see
eg
assess
larg
sampl
group
high
throughput
method
need
much
preanalyt
sampl
cleanup
prefer
other
previous
search
crc
serum
protein
profil
surfaceenhanc
laser
desorpt
ionisationtim
flight
mass
spectrometri
selditof
ms
although
much
debat
surround
technolog
sever
discrimin
protein
studi
overlap
indic
interlaboratori
reproduc
valid
howev
studi
crc
patient
advanc
diseas
compar
healthi
control
ultim
goal
use
protein
profil
earli
diagnosi
possibl
even
precancer
stage
prospect
studi
need
heterogen
popul
patient
risk
furthermor
protein
profil
suitabl
followup
crc
patient
level
reflect
respons
treatment
relaps
comparison
tissu
protein
profil
give
insight
pathophysiolog
mechan
underli
accompani
crc
addit
compar
tissu
protein
profil
differ
stage
along
socal
adenomacarcinoma
sequenc
provid
knowledg
extent
transform
occur
differ
histolog
subtyp
polyp
current
studi
aim
prospect
valid
previou
crc
serum
protein
profil
selditof
ms
new
popul
patient
indic
colonoscopi
colonoscopi
patient
attribut
control
group
group
adenomat
polyp
group
colorect
cancer
serum
protein
profil
group
compar
discrimin
protein
addit
serum
protein
profil
patient
colorect
cancer
baselin
compar
week
surgic
resect
tumour
lastli
tissu
protein
profil
acquir
polyp
crc
tissu
compar
patient
year
old
histori
malign
cur
treat
melanoma
cervix
carcinoma
exclud
present
indic
colonoscopi
depart
gastroenterolog
hepatolog
present
treatment
colorect
tumour
ask
particip
studi
patient
includ
two
hospit
slotervaart
hospit
netherland
cancer
instituteantoni
van
leeuwenhoek
hospit
amsterdam
netherland
studi
approv
local
medic
ethic
committe
institut
inform
consent
everi
patient
obtain
serum
sampl
collect
particip
either
colonoscopi
applic
treatment
colorect
tumour
fig
follow
colonoscopi
diagnosi
record
individu
three
group
defin
control
con
adenomat
polyp
ap
colorect
cancer
crc
second
serum
sampl
collect
crc
patient
least
week
surgeri
adjuv
chemotherapi
given
serum
collect
done
follow
strict
protocol
sampl
collect
bd
tube
becton
dickinson
breda
netherland
allow
clot
exactli
min
room
temperatur
centrifug
g
min
room
temperatur
sampl
immedi
aliquot
store
tissu
sampl
collect
patient
adenomat
polyp
cm
crc
tissu
collect
dri
tissu
section
snap
frozen
liquid
nitrogen
immedi
collect
depart
patholog
tissu
store
liquid
nitrogen
analysi
snap
frozen
tissu
section
disintegr
deep
frozen
state
pulveris
microdismembran
ii
sartoriu
ag
germani
first
tissu
cut
smaller
block
place
precool
shake
flask
stainless
steel
ball
pulveris
three
round
shake
cool
liquid
nitrogen
min
ten
mg
result
frozen
tissu
powder
ad
denatur
buffer
consist
urea
dimethylammonio
chap
dithiotreitol
dtt
store
analysi
measur
protein
concentr
lysat
thaw
ice
centrifug
rpm
min
supernat
collect
protein
profil
protein
concentr
supernat
determin
use
kit
ge
healthcar
diegem
belgium
accord
manufactur
instruct
serum
sampl
analys
selditof
ms
biorad
laboratori
hercul
ca
usa
chip
describ
previous
sampl
process
manual
therefor
sampl
randomli
attribut
one
nine
measur
seri
analysi
seri
measur
duplic
one
day
sampl
alloc
chip
randomis
duplic
spot
differ
chip
take
account
interchip
variabl
pre
postsurgeri
sera
crc
patient
assess
similarli
separ
analysi
tissu
lysat
also
analys
duplic
separ
seri
use
procedur
serum
amount
lysat
appli
chip
adjust
protein
concentr
sampl
protein
chip
read
use
pbsiic
proteinchip
reader
biorad
laboratori
data
collect
kda
averag
laser
shot
per
spectrum
laser
intens
detector
sensit
collect
focu
mass
set
da
set
tissu
analysi
optimis
independ
result
averag
laser
shot
per
spectrum
intens
detector
sensit
focu
mass
da
masstocharg
mz
valu
calibr
extern
allinon
peptid
mixtur
biorad
laboratori
raw
data
acquir
spectra
export
ciphergen
proteinchip
softwar
biorad
laboratori
baselin
correct
normalis
peak
detect
peak
cluster
perform
use
masda
rpackag
http
bioinformaticsnkinl
individu
spectra
normalis
centr
around
zero
divid
standard
deviat
peak
detect
cluster
perform
within
maximum
window
current
mz
duplic
measur
averag
group
differ
con
ap
crc
serum
tissu
pre
postsurgeri
sera
assess
nonparametr
statist
test
correct
multipl
test
use
benjaminihochberg
correct
pvalu
defin
statist
signific
differ
classif
model
form
support
vector
machin
svm
built
pair
wise
combin
class
ie
con
vs
crc
con
vs
ap
ap
vs
crc
radial
basi
kernel
use
gener
good
perform
doubleloop
crossvalid
procedur
use
estim
paramet
assess
model
perform
optimis
cost
paramet
c
kernel
paramet
done
within
inner
loop
wherea
outer
loop
use
estim
perform
chosen
model
independ
test
set
take
account
larg
prior
probabl
classifi
con
due
much
larger
sampl
size
group
perform
estim
use
mean
ratio
true
posit
true
neg
rate
rpackag
svmpath
use
model
build
process
statist
analys
perform
spss
version
spss
inc
chicago
il
usa
total
patient
indic
colonoscopi
ask
particip
studi
tabl
one
hundr
twentytwo
patient
exclud
serum
sampl
analysi
found
inelig
accord
inclus
criteria
give
inform
consent
provid
serum
sampl
analysi
show
colonoscopi
total
number
patient
evalu
serum
protein
profil
patient
exclud
serum
analys
significantli
differ
gender
older
vs
year
p
slightli
differ
indic
colonoscopi
diagnos
compar
evalu
patient
compris
fewer
patient
rectal
blood
loss
vs
patient
chang
defec
vs
also
diagnos
somewhat
differ
exclud
patient
fewer
patient
ap
vs
patient
crc
vs
group
compar
evalu
patient
tissu
obtain
individu
crc
characterist
assess
patient
describ
tabl
detect
significantli
differ
peak
con
ap
crc
tabl
peak
differ
con
crc
also
significantli
differ
ap
crc
signific
differ
observ
con
ap
sever
significantli
differ
peak
correspond
mass
apolipoprotein
ci
fragment
without
ntermin
threonin
prolin
kda
doubli
charg
molecul
kda
previous
identifi
biomark
candid
kda
detect
current
analys
mz
express
differ
observ
correl
age
polyp
size
observ
discrimin
peak
detect
peak
use
modelbuild
svm
howev
suitabl
model
obtain
discrimin
con
ap
crc
mean
crossvalid
perform
svm
classifi
comparison
con
vs
crc
con
vs
ap
ap
vs
crc
respect
pre
postsurgeri
serum
sampl
avail
crc
patient
mark
tabl
postsurgeri
sampl
drawn
day
surgeri
signific
differ
observ
pre
postsurgeri
serum
protein
profil
sixteen
patient
demonstr
increas
mz
postsurgeri
well
patient
mz
postsurgeri
peak
intens
peak
correl
time
surgeri
collect
postsurgeri
serum
sampl
r
p
patient
tissu
protein
profil
evalu
tabl
tissu
classifi
accord
histolog
con
hyperplast
polyp
ap
tubular
tubulovil
polyp
respect
crc
tumour
tissu
polyp
carcinoma
situ
found
peak
significantli
differ
tissu
tabl
mani
show
gradual
increas
decreas
go
con
ap
crc
fig
peak
mz
kda
found
increas
crc
compar
ap
con
also
across
differ
subtyp
polyp
fig
eg
mz
peak
intens
polyp
carcinoma
situ
larg
overlap
crc
tissu
compar
fig
b
wherea
peak
intens
tubular
polyp
closer
hyperplast
polyp
howev
unabl
classifi
patient
suffici
good
sensit
specif
base
tissu
protein
profil
exampl
tissu
spectra
shown
figur
correl
polyp
size
observ
peak
r
p
r
p
r
p
da
r
p
current
studi
prospect
valid
previou
serum
protein
profil
crc
patient
advanc
diseas
new
popul
patient
mostli
earlystag
crc
adenomat
polyp
control
indic
colonoscopi
knowledg
first
largescal
clinic
studi
previous
establish
crc
serum
protein
profil
valid
clinic
relev
popul
patient
indic
colonoscopi
elig
patient
ask
particip
studi
evalu
serum
analysi
small
differ
evalu
nonevalu
patient
older
age
latter
group
differ
indic
diagnos
colonoscopi
comparison
latter
indic
patient
least
sever
diagnosi
like
nonevalu
patient
whose
complaint
disappear
like
miss
colonoscopi
wherea
patient
crc
like
give
consent
diseas
omiss
extrem
elig
popul
may
preclud
detect
differ
patient
control
confirm
decreas
express
mz
kda
two
ion
apolipoprotein
ci
current
popul
crc
patient
recent
shown
one
earlier
biomark
candid
ntermin
albumin
fragment
kda
product
proteolysi
storag
explain
observ
peak
analysi
lack
express
differ
peak
da
kda
like
relat
differ
patient
characterist
sampl
handl
protocol
compar
previou
studi
find
signific
differ
pre
postsurgeri
serum
protein
profil
apolipoprotein
ci
synthesis
mainli
liver
small
intestin
plausibl
resect
tumour
immedi
influenc
abund
protein
howev
observ
correl
postsurgeri
peak
intens
mz
kda
time
surgeri
serum
collect
indic
apolipoprotein
ci
level
return
normal
timelag
month
surgeri
data
shown
also
cea
time
lag
week
level
surgeri
common
level
return
normal
although
valid
serum
decreas
apolipoprotein
ci
group
patient
earlystag
crc
could
use
acquir
serum
tissu
protein
profil
correct
classif
con
ap
crc
expect
potenti
classifi
patient
serum
protein
profil
would
lower
current
popul
sinc
compar
patient
earlystag
diseas
control
group
essenti
healthi
background
nois
introduc
analysi
howev
analysi
popul
essenti
assess
clinic
util
type
mass
spectrometr
profil
importantli
could
discern
patient
ap
con
would
advantag
establish
patient
need
colonoscopi
remov
ap
quantit
method
need
determin
actual
differ
serum
level
apolipoprotein
ci
con
ap
crc
suitabl
cutoff
level
establish
clinic
use
approach
taken
eg
habermann
et
al
use
elisa
quantit
complement
desarg
valid
ms
result
although
other
suggest
serum
protein
profil
differ
chip
surfac
good
sensit
specif
discrimin
ap
crc
result
remain
valid
larger
patient
group
therefor
current
serum
protein
profil
yet
replac
endoscop
screen
addit
regard
specif
apolipoprotein
ci
crc
must
remark
similar
decreas
apolipoprotein
ci
protein
peak
similar
mass
describ
sever
type
cancer
benign
diseas
henc
potenti
use
crc
seem
confin
followup
patient
besid
serum
compar
polyp
crc
tissu
order
elucid
sequenti
protein
express
differ
occur
develop
hyperplast
polyp
carcinoma
situ
crc
addit
compar
discrimin
serum
protein
tissu
found
protein
peak
kda
might
repres
apolipoprotein
ci
tissu
sampl
contrari
serum
peak
exhibit
higher
abund
crc
ap
con
howev
serum
protein
level
necessarili
reflect
process
occur
tissu
exampl
apolipoprotein
ai
decreas
serum
due
less
synthesi
liver
increas
tissu
due
local
synthesi
gradual
increas
peak
other
obviou
look
differ
histolog
subtyp
polyp
indic
subtyp
inde
reflect
extent
transform
polyp
also
relationship
peak
intens
polyp
size
observ
peak
indic
polyp
size
could
surrog
measur
extent
malign
transform
whether
hyperplast
polyp
fact
premalign
stage
crc
suggest
hyperplast
polyposi
syndrom
innoc
polyp
remain
establish
direct
comparison
hyperplast
polyp
normal
tissu
protein
profil
normal
tissu
analys
current
studi
attempt
find
diagnost
tissu
protein
limit
util
tissu
matrix
screen
purpos
due
need
colonoscopi
sever
report
describ
increas
level
crc
tissu
current
studi
also
found
peak
mass
correspond
protein
name
mz
first
peak
also
found
increas
crc
compar
ap
con
studi
pair
wise
comparison
con
crc
found
mz
borderlin
significantli
increas
crc
p
fact
compar
normal
mucosa
crc
use
whole
tumour
tissu
instead
microdissect
tumour
cell
like
caus
discrep
publish
report
wherea
other
also
report
presenc
peptid
serum
suggest
potenti
serum
marker
detect
serum
current
bind
condit
potenti
diagnost
biomark
crc
seem
limit
serum
level
also
increas
cancer
sever
benign
immunolog
condit
furthermor
tissu
protein
profil
result
indic
express
increas
crc
yet
polyp
hamper
use
identif
polyp
malign
potenti
yet
suggest
previous
may
use
marker
crc
prognosi
monitor
unlik
mell
et
al
observ
signific
express
differ
ap
crc
kda
could
correspond
heat
shock
protein
calgizzarin
may
also
caus
abovement
differ
tissu
process
conclud
valid
decreas
apolipoprotein
ci
serum
level
crc
larg
prospect
studi
selditof
ms
yet
quantit
method
apolipoprotein
ci
measur
develop
use
establish
reliabl
cutoff
valu
clinic
use
addit
found
gradual
chang
protein
express
along
differ
stage
adenomacarcinoma
sequenc
may
help
discern
adenomat
polyp
malign
potenti
